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Epstein-Barr virus (EBV) latent membrane protein 1 (LMP1) activates multiple signaling pathways.
Two regions, C-terminal-activating region 1 (CTAR1) and CTAR2, have been identified within the cyto-
plasmic carboxy terminal domain that activates NF-B. CTAR2 activates the canonical NF-B pathway,
which includes p50/p65 complexes. CTAR1 can activate both the canonical and noncanonical pathways to
produce multiple distinct NF-B dimers, including p52/p50, p52/p65, and p50/p50. CTAR1 also uniquely
upregulates the epidermal growth factor receptor (EGFR) in epithelial cells. Increased p50-Bcl-3 com-
plexes have been detected by chromatin precipitation on the NF-B consensus motifs within the egfr
promoter in CTAR1-expressing epithelial cells and nasopharyngeal carcinoma cells. In this study, the
mechanism responsible for the increase in Bcl-3 has been further investigated. The data indicate that
LMP1-CTAR1 induces Bcl-3 mRNA and increases the nuclear translocation of both Bcl-3 and p50.
LMP1-CTAR1 constitutively activates STAT3, and this activation was not due to the induction of inter-
leukin 6 (IL-6). In LMP1-CTAR1-expressing cells, increased levels of activated STAT3 were detected by
chromatin immunoprecipitation on STAT-binding sites located within both the promoter and the second
intron of Bcl-3. A STAT3 inhibitor significantly reduced the activation of STAT3, as well as the CTAR1-
mediated upregulation of Bcl-3 and EGFR. These data suggest that LMP1 activates distinct forms of
NF-B through multiple pathways. In addition to activating the canonical and noncanonical pathways,
LMP1-CTAR1 constitutively activates STAT3 and increases Bcl-3. The increased nuclear Bcl-3 and p50
homodimer complexes positively regulate EGFR expression. These results indicate that LMP1 likely
regulates distinct cellular genes by activating specific NF-B pathways.
Epstein-Barr virus (EBV) latent membrane protein 1
(LMP1) is an essential factor in EBV-induced transformation
and is expressed in many of the malignancies associated with
EBV, including posttransplant lymphoma, Hodgkin’s disease,
and nasopharyngeal carcinoma (NPC) (12, 28, 51, 66). LMP1 is
considered a constitutively activated member of the tumor
necrosis factor receptor family and binds tumor necrosis fac-
tor-associated factors (TRAFs) (27, 41, 44). Two major signal-
ing domains have been identified within the cytoplasmic C-
terminal domains of LMP1, CTAR1, and CTAR2 that can
activate NF-B (25). However, CTAR1 has several unique
properties and is essential for transformation, while CTAR2 is
dispensable (34, 35). LMP1-CTAR1 uniquely induces expres-
sion of the epidermal growth factor receptor (EGFR) at the
mRNA level, and this induction requires NF-B and is medi-
ated through the TRAF signaling pathway (41–43). Subse-
quent studies have identified other genes that are uniquely
activated by LMP1-CTAR1, including TRAF1 and EBI3 (14).
The NF-B transcription factors dimerize and bind NF-B
consensus sequences in cellular and viral promoters to regulate
the expression of genes controlling inflammation, cell cycle
regulation, apoptosis, and oncogenesis (21, 38). There are five
mammalian NF-B family members, including p50, p52, p65
(RelA), c-Rel, and RelB. The activation of NF-B family
members is regulated through interactions with inhibitors of
NF-B (IB), which sequester NF-B members in the cytosol.
Activation of a kinase cascade that includes IB kinase alpha
(IKK), IKK, and IKK results in the phosphorylation, ubiq-
uitination, and degradation of an IB, leading to the release
and nuclear translocation of NF-B. The p50 and p52 precur-
sor proteins, p105 and p100, respectively, can also function as
IB. Early studies initially showed that LMP1-CTAR1 acti-
vated multiple forms of NF-B, including p50/p65, p50/p52,
and p50 homodimers, and also greatly increased the processing
of p100 to p52 in epithelial cells and the nuclear translocation
of p50 (41, 48). It has subsequently been shown that the in-
duction of processing of p100 represents another mechanism
for the activation of NF-B. This is considered the noncanoni-
cal NF-B pathway, and the activation of this pathway is spe-
cific for LMP1-CTAR1 (1, 15, 33, 53). Noncanonical activation
of NF-B requires IKK and is mediated through the NF-B-
inducing kinase NIK to induce the processing of p100 and to
activate p52/relB. Canonical activation requires IKK and
IKK to activate p50/p65. The activation of specific genes by
LMP1 has been linked to the canonical and noncanonical path-
ways by use of engineered mouse fibroblasts (33). MIP-2 was
activated by the canonical pathway, which is IKK/IKK de-
pendent. Induction of the cellular chemokine CXCR4 required
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IKK and was considered activated by the noncanonical path-
way. An atypical pathway was also identified that was IKK
dependent but independent of IKK and that regulated the
expression of MIG and I-TAC.
The link between LMP1-CTAR1 activation of unique genes
and distinct forms of NF-B was demonstrated in studies that
showed that LMP1-CTAR1 induced the binding of NF-B p50
and Bcl-3 to the NF-B sites in the egfr promoter in C33A cells
(59). LMP1 effectively induces the nuclear translocation of
p50, and p50/p50 homodimers are the major NF-B complex
activated in LMP1-expressing cells and EBV-positive xe-
nografted NPC tumors (48, 58, 59). In addition, elevated levels
of p50/p50 homodimers and Bcl-3 are found in classical
Hodgkin’s lymphoma and anaplastic large-cell lymphomas that
are associated with EBV infection (37).
In this study, the effects of LMP1-CTAR1 on Bcl-3 expres-
sion and EGFR induction were further evaluated. LMP1-
CTAR1 induced Bcl-3 transcription, resulting in increased lev-
els of nuclear Bcl-3. The transcriptional activation of Bcl-3
required STAT3, which bound to sites within the Bcl-3 pro-
moter and intron 2. LMP1-CTAR1 expression increased both
the serine and tyrosine phosphorylations of STAT3 that are
indicative of activation. These data indicate that LMP1 acti-
vates distinct forms of NF-B through different pathways. In
addition to activating the canonical and noncanonical path-
ways, LMP1-CTAR1 also activates p50/p50 homodimers by
increasing the expression of Bcl-3 through its effects on
STAT3.
MATERIALS AND METHODS
Retrovirus production and transduction. Recombinant retrovirus produc-
tion and transduction were performed as previously described to establish
C33A stable cell lines expressing full-length LMP1, deletion mutant
CTAR1(1-231) (contains only CTAR1 and not CTAR2), deletion mutant
CTAR2(d187-351) (contains only CTAR2 and not CTAR1), or vector control
pBabe (34). Briefly, 80% confluent 293T cells were triple transfected using
FuGENE 6 transfection reagent (Roche) according to the manufacturer’s
instructions with 5 g pBabe (vector), pBabe-hemagglutinin (HA)-LMP1,
pBabe-HA-1-231, or pBabe-HA-d187-351 and 5 g pVSV-G- and 5 g pGag/
Pol-expressing plasmids. After 24 h of incubation at 37°C, media were re-
placed with fresh media and cells were incubated at 33°C for another 24 h.
Cell supernatant then was centrifuged at 1,000  g for 5 min to remove cell
debris and virus-containing supernatant was collected. C33A cells with 70 to
80% confluence were then transduced with clarified supernatant with 4 g/ml
Polybrene for 24 h at 37°C.
Cell culture and stable cell lines. C33A cervical carcinoma cells were cultured
in Dulbecco’s modified Eagle’s medium (Gibco) supplemented with 10% fetal
bovine serum (Sigma) and antibiotic/antimycotic (Gibco) at 37°C with 5% CO2.
C33A stable cell lines expressing full-length LMP1, CTAR1(1-231),
CTAR2(d187-351), or vector control pBabe were established by retroviral trans-
duction followed by selection and passage in the presence of 1 g/ml puromycin
(Sigma).
Fractionation of cells. After cultured cells reached 80 to 90% confluence,
cells were scrape harvested, washed once with cold phosphate-buffered saline
(PBS; Gibco), centrifuged at 1,000  g, and lysed with radioimmunoprecipitation
assay buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 1 mM EDTA, 1% NP-40,
0.1% sodium dodecyl sulfate, 0.1% deoxycholic acid) supplemented with phen-
ylmethylsulfonyl fluoride (PMSF), sodium orthovanadate (Na3VO4), protease,
and phosphatase inhibitor cocktail (Sigma). Lysates were then clarified by cen-
trifugation at 13,000 rpm, 4°C for 15 min, and supernatants containing whole-cell
lysates were removed to new tubes. Nuclear extracts were made as previously
described with slight modification (59). Briefly, cells were scrape harvested,
washed once with cold PBS, and lysed by incubation in a hypotonic buffer (20
mM HEPES, 10 mM KCl, 0.1 mM EDTA, 0.1 mM EGTA) supplemented with
PMSF, Na3VO4, protease, and phosphatase inhibitor cocktail (Sigma) for 15 min
on ice. Nonidet P-40 was then added to a final concentration of 1%, followed by
1 min of vortexing. Nuclei were pelleted by low-speed centrifugation at 1,200 rpm
for 10 min at 4°C, and the supernatant was collected as a cytoplasmic fraction.
The nuclear fractions were purified using the Optiprep reagent (Sigma) as
directed by the manufacturer and as previously described (58). Nuclei were lysed
with nuclear extraction buffer (20 mM Tris-HCl [pH 8.0], 420 mM NaCl, 1.5 mM
MgCl2, 0.2 mM EDTA, 25% glycerol, PMSF, Na3VO4, protease, and phos-
phatase inhibitor cocktail 	) with the salt concentration adjusted to 400 mM with
5 M NaCl. All lysates were stored at 
80°C.
Western blot analysis. Protein concentrations of cell lysates were deter-
mined using the Bio-Rad DC protein assay system according to the manu-
facturer’s instructions. Equal amounts of protein were used for sodium do-
decyl sulfate-polyacrylamide gel electrophoresis and transferred to Optitran
(Schleicher and Schuell) for Western blot analysis. Primary antibodies used
include anti-p50, anti--actin, anti-GRP78, anti-STAT3, anti-poly (ADP-
ribose) polymerase (anti-PARP) (Santa Cruz), anti-Bcl-3 (Upstate Biotech-
nology), anti-phospho-STAT3 (Ser 727 and Tyr 705) (Cell Signaling), anti-
phospho-EGFR (Tyr 1068) (BD Biosciences), and anti-HA tag (Covance). A
rabbit antiserum raised against the carboxyl-terminal 100 amino acids of the
EGFR fused to glutathione S-transferase (kindly provided by H. Shelton
Earp) was used to detect total EGFR. Secondary antibodies used to detect
bound proteins include horseradish peroxidase-conjugated anti-mouse, anti-
rabbit (Amersham Pharmacia), and anti-goat (DAKO). Blots were developed
using Pierce Supersignal West Pico chemiluminescence system followed by
exposure to film.
ChIP analysis. Chromatin immunoprecipitation (ChIP) analysis was per-
formed using a ChIP kit (Upstate Biotechnology) according to the manufactur-
er’s protocol. Briefly, cells were cultivated in 100-mm plates to 90% confluence
and scrape harvested. Cells were then fixed for 5 min in 1% freshly made
formaldehyde, washed with PBS, and lysed for 10 min in lysis buffer provided in
the kit. Chromatin was sheared by sonication to an average size of 200 to 500
bp, clarified, and precleared for 1 h at 4°C with salmon sperm DNA-saturated
protein G-Sepharose beads. The supernatant was incubated with normal rabbit
immunoglobulin G, with anti-STAT3 (Santa Cruz), or with anti-phospho-STAT3
(Ser 727; Cell Signaling) and nutated overnight at 4°C. Lysates were immuno-
precipitated with salmon sperm DNA-saturated protein G-Sepharose beads for
1 h at 4°C and washed extensively according to the manufacturer’s instructions.
Input and immunoprecipitated protein/DNA complexes were eluted at room
temperature, and the cross-linking was reversed overnight at 65°C in the pres-
ence of 200 mM NaCl. After RNase A (37°C for 30 min) and proteinase K (45°C
for 2 h) treatment, sample DNAs were purified as directed by the manufacturer
for further analysis. PCR of ChIP products was performed with HotStar Taq
polymerase (Qiagen), and primer pairs used for different ChIP target sequences
include the following: for Bcl-3-Pro, 5 TGACCCGGACTCAACCCCAG 3 and
5 TCTCCTCCCCTCCTCTCCCTC 3; for HS3, 5 CGCTTCCTCCAACCTT
AACC 3 and 5 TGCCCAGTCCCTAACCTCTT 3; and for HS4, 5 CATTC
GAGGATGGAAGTTGG 3 and 5 CAGGGTTAAGTGAGGGCAGA 3.
QRT-PCR. Total cell RNA was isolated using an RNeasy kit as directed by the
manufacturer (Qiagen). Primer pairs used in this paper include the following: for
actin, 5 TCACCCACACTGTGCCCATCTACGA 3 and 5 CAGCGGAACC
GCTCATTGCCAATGG 3; for EGFR, 5 CTGCGTCTCTTGCCGGAATG 3
and 5 TTGGCTCACCCTCCAGAAGG 3; for Bcl-3, 5 ACAACAGCCTTA
GCATGGTG 3 and 5 GCTGAGTGCAGGGCGGAGCT 3; and for interleu-
kin 6 (IL-6), 5 AGCCACTCACCTCTTCAGAAC 3 and 5 GCTGCTTTCAC
ACATGTTACTCTT 3. Quantitative real-time PCR (QRT-PCR) was performed
using a Quantitect SYBR green reverse transcription-PCR kit (Qiagen) according to
the manufacturer’s instructions. Amplification of PCR products was detected using
ABI 7900HT sequence detection system (Applied Biosystems) and analyzed using
SDS 2.0 software (Applied Biosystems). The cycle threshold (CT) was determined as
the number of PCR cycles required for a given reaction to reach an arbitrary
fluorescence value within the linear amplification range. The change in CT (CT)
was determined between the same target gene primer sets and different samples, and
the change in CT (CT) was determined by adjusting for the difference in the
number of cycles required for actin to reach the CT. The severalfold change was
determined as 2CT, since each PCR cycle results in a twofold amplification of each
PCR product. QRT-PCR was also performed to amplify ChIP products and primer
pairs used for different ChIP target sequences, including the following: for Bcl-3-Pro,
5 TGACCCGGACTCAACCCCAG 3 and 5 TCTCCTCCCCTCCTCTCCCTC
3; for HS3, 5 CGCTTCCTCCAACCTTAACC 3 and 5 AAGAGGAGCCGGT
GGCGCAG 3; and for HS4, 5 TTACTGGAAGTCCGAGGGCT 3 and 5 TTC
AGAGAAACCGTCCAGGC 3.
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RESULTS
CTAR1 of LMP1 induces EGFR mRNA and protein. The
CTAR1 domain of LMP1 has previously been shown to induce
the expression of the EGFR. The full-length LMP1 and the
1-231 (contains only CTAR1 and not CTAR2), and d187-351
(contains only CTAR2 and not CTAR1) constructs previously
cloned into the pBabe retroviral expression vector were stably
transduced into C33A epithelial cells (Fig. 1B) (17). Expres-
sion of LMP1 and the CTAR deletion mutants and EGFR
expression were evaluated by immunoblotting (Fig. 1A). As
previously shown, LMP1 and CTAR1 but not CTAR2 of
LMP1 induced EGFR expression, with highly elevated levels
induced by CTAR1 (43). In addition, high levels of phosphory-
lated, activated EGFR were detected using a phosphospecific
antibody, indicating that the EGFR induced by CTAR1 is
functionally active. QRT-PCR confirmed previous studies that
indicated that LMP1 upregulates EGFR at the mRNA level
(42) (Fig. 1C). Quantification of the immunoblot indicated that
in C33A cells, LMP1 and CTAR1 induced EGFR mRNA
expression 7-fold and 17-fold, respectively. LMP1-CTAR2 did
not affect the EGFR mRNA level or the levels of phosphory-
lated EGFR protein. Although the levels of LMP1 expression
were very similar, the total and activated EGFR levels induced
by LMP1-CTAR1 were significantly higher than those induced
by full-length LMP1. This suggests that CTAR2 or sequences
between CTAR1 and CTAR2 may inhibit the ability of
CTAR1 to induce specific targets, such as EGFR.
LMP1-CTAR1 upregulates Bcl-3 expression and induces
nuclear translocation of Bcl-3 and p50. In studies of EBV-
positive NPC xenografts, p50 and Bcl-3 were detected by ChIP
to be bound to the EGFR promoter, while other forms of
NF-B were not detected (58). In addition, in C33A cells,
transient overexpression of Bcl-3 and/or p50 slightly increased
EGFR expression and p50/Bcl-3 complexes could be detected
by ChIP on the EGFR promoter in C33A cells expressing
LMP1-CTAR1 (59). To determine the effect of LMP1 and
LMP1-CTAR1 on the localization and expression levels of
Bcl-3 and p50, lysates of whole-cell and nuclear fractions were
analyzed by Western blotting. Both LMP1 and LMP1-CTAR1
increased levels of Bcl-3 in the whole-cell lysates; increases
were approximately 2.1-fold and 4.6-fold, respectively (Fig.
2A). Elevated levels of p50 and Bcl-3 were also detected in the
nuclei of the LMP1-expressing C33A cells (Fig. 2B). Equal
loading was confirmed by immunoblotting for the cytosolic and
nuclear proteins GRP78 and PARP. Quantification using the
ImageJ software and normalization to the intensity of PARP
bands indicated that LMP1-expressing C33A cells had a 1.4-
fold increase in nuclear Bcl-3 and that LMP1-CTAR1-express-
ing cells had an approximately 1.9-fold increase. LMP1-
CTAR2 did not affect the levels of whole-cell or nuclear Bcl-3
compared to vector control cells. Expression of LMP1 and
LMP1-CTAR1 also significantly induced the nuclear translo-
cation of NF-B p50 by approximately 13- and 16-fold, respec-
tively (Fig. 2B) (48). Although LMP1-CTAR2 induces higher
levels of NF-B activity in reporter assays, in C33A cells ex-
pressing LMP1-CTAR2, nuclear p50 was increased only five-
fold (25, 57). QRT-PCR using Bcl-3-specific primers indicated
that Bcl-3 mRNA was increased by inductions of approxi-
mately 1.9-fold and 3.3-fold in LMP1- and LMP1-CTAR1-
expressing cells (Fig. 2C). LMP1-CTAR2 did not affect the
Bcl-3 mRNA level. These results indicate that LMP1-CTAR1
not only induces the nuclear translocation of NF-B Bcl-3 and
p50 but also transcriptionally activates Bcl-3.
STAT3 is constitutively activated by LMP1-CTAR1. Previ-
ous studies have shown that LMP1 can activate signal trans-
ducer and activator of transcription 3 (STAT3) and that the
FIG. 1. CTAR1 of LMP1 upregulates EGFR mRNA levels. (A) LMP1 and EGFR expression was examined by Western blot analysis for C33A
cells expressing HA-tagged LMP1, deletion mutant 1-231, and deletion mutant d187-351. (B) A schematic of LMP1, 1-231, and d187-351
constructs. (C) Expression of EGFR mRNA in stable C33A cells was analyzed by QRT-PCR. Severalfold change was normalized to the value for
actin. Data shown are the mean values of three independent experiments, each being performed in triplicate.
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activated STAT3 may regulate LMP1 expression through ef-
fects on the novel LMP1 promoter within the terminal repeats
that is active in NPC (9, 10, 32, 52). STAT3 has also been
shown to transcriptionally activate Bcl-3 through enhancer se-
quences detected within the Bcl-3 introns (4). The transcrip-
tional activity of STAT3 is regulated by phosphorylation. Phos-
phorylation at tyrosine 705 induces Bcl-3 dimerization, while
phosphorylation at serine 727 affects DNA binding and tran-
scriptional activity (3, 13). To determine the effects of LMP1
and CTAR1 on STAT3 activation, serine- and tyrosine-phos-
phorylated STAT3 was identified using phosphospecific
STAT3 antibodies, quantified by ImageJ, and normalized to
the loading control, GRP78 (Fig. 3A). The severalfold induc-
tion is indicated beneath the corresponding bands of one rep-
resentative experiment out of three independent attempts.
Cells expressing LMP1 had an approximately 2.4-fold increase
in tyrosine-phosphorylated STAT3 and a 2.5-fold increase in
serine-phosphorylated STAT3 compared to what was seen for
the vector control. Cells expressing LMP1-CTAR1 had an
approximately threefold increase in tyrosine-phosphorylated
STAT3 and a fourfold increase in serine-phosphorylated
STAT3. LMP1-CTAR2 had an approximately 1.6-fold increase
in tyrosine-phosphorylated STAT3 and a 1.7-fold increase in
serine-phosphorylated STAT3. Although the levels of phos-
phorylated STAT3 were increased by LMP1, the total level of
STAT3 was not affected.
Cucurbitacin is a specific inhibitor of STAT3 activation
through effects on the Janus kinases (JAKs) (2, 31). Treatment
of the LMP1-CTAR1-expressing C33A cells with cucurbitacin
reduced both the tyrosine and serine phosphorylation of
STAT3 induced by LMP1-CTAR1 (Fig. 3B). The effects of
cucurbitacin were dose dependent in that 1 M of cucurbitacin
reduced LMP1-CTAR1-mediated induction to the level de-
tected in control cells, while 10 M eliminated phosphorylated
STAT3. Importantly, treatment with cucurbitacin significantly
reduced the effects of LMP1-CTAR1 on Bcl-3 and EGFR, and
at 10 M expression of Bcl-3 was eliminated. QRT-PCR of
EGFR mRNA indicated that EGFR mRNA was reduced 63%
and 86% by 1 M and 10 M of cucurbitacin (Fig. 3C). These
results suggest that CTAR1-mediated STAT3 activation is re-
quired for Bcl-3 induction and at least partially responsible for
the induction of EGFR.
Previous studies have shown that LMP1 can induce the ex-
pression of IL-6, resulting in the activation of STAT3 (4, 9, 10,
16). To determine whether LMP1-mediated STAT3 activation
resulted from IL-6 induction in C33A cells, QRT-PCR was
performed to detect IL-6 mRNA (Fig. 4). In C33A cells, IL-6
mRNA levels were induced by LMP1, LMP1-CTAR1, and
LMP1-CTAR2 to 1.6-, 2.7-, and 4.2-fold, respectively. The
highest induction was detected in LMP1-CTAR2 cells that did









































































































FIG. 2. CTAR1 of LMP1 upregulates Bcl-3 and induces nuclear
translocation of Bcl-3 and p50. (A) Bcl-3 expression in stable C33A
cells was examined by Western blotting and quantitated using ImageJ
software. Data shown are the mean values of three independent ex-
periments. (B) Nuclear p50 and Bcl-3 in C33A stable cells were shown
by Western blotting and quantitated using ImageJ software. Data
shown are the mean values of four and three independent experiments
for Bcl-3 and p50, respectively. Severalfold change was normalized to
GRP78 and PARP values in panels A and B, respectively. (C) mRNA
of Bcl-3 was examined by QRT-PCR. Severalfold change was normal-
ized to the value for actin. Data shown are the mean values of three
independent experiments, each being performed in triplicate.
FIG. 3. CTAR1 of LMP1 upregulates Bcl-3 and EGFR by activat-
ing STAT3. (A) Total and phosphorylation levels of STAT3 were
examined by Western blotting. Severalfold inductions are listed be-
neath their corresponding bands. The blot is representative of three
independent experiments. (B) The phosphorylation of STAT3, as well
as the expression of Bcl-3 and EGFR, was examined for 1-231-express-
ing C33A cells treated with the STAT3-specific inhibitor cucurbitacin.
(C) mRNA of EGFR was examined by QRT-PCR in the pBabe con-
trol, 1-231 cells treated with dimethyl sulfoxide (DMSO), and 1-231
cells treated with cucurbitacin. Severalfold change was normalized to
the value for actin. Data shown are the mean values of four indepen-
dent experiments, each being performed in triplicate.
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stitutively activated by LMP1-CTAR1 in C33A cells through
mechanisms that are not dependent on IL-6 induction.
LMP1-CTAR1 induces STAT3 binding to sites in the Bcl-3
promoter and introns. Two enhancers that mediate STAT3
induction of Bcl-3, HS3 and HS4, have been identified within
introns of Bcl-3 (4). HS3 contains one and HS4 has three
putative STAT3 binding sites, respectively (Fig. 5A). The on-
line program ALGGEN-PROMO, which can be accessed on-
line at http://www.lsi.upc.es/alggen under the research link,
was also used to predict STAT3 binding sites in the Bcl-3
promoter. One potential site (Bcl-3-Pro) was identified at ap-
proximately 1,200 bp upstream of the Bcl-3 transcriptional
start site (Fig. 5A) (18, 39). To determine if LMP1-CTAR1
induces binding of STAT3 to these putative binding sites, ChIP
analysis was performed with C33A cells stably expressing the
pBabe vector control and LMP1-CTAR1 using primers specific
for each of the three predicted sites (Fig. 5B). In the pBabe
control cells, precipitation with STAT3 or serine-phosphory-
lated STAT3 antibodies did not increase the amplification
compared to what was seen for precipitation with normal rab-
bit immunoglobulin. For LMP1-CTAR1 cells, precipitation
with STAT3 antibody slightly increased the amplification of all
three putative STAT3 binding sites. However, precipitation
with the serine-phosphorylated specific STAT3 antibody de-
tected increased binding between STAT3 and all three putative
STAT3 binding sites in the presence of LMP1-CTAR1. LMP1-
CTAR1 did not increase interaction between STAT3 and a
nonspecific target within EGFR Exon2, indicating the speci-
ficity of the effect (data not shown). This result was confirmed
using quantitative PCR to amplify ChIP products, and the data
were normalized to determine the severalfold level of enrich-
ment in LMP1-CTAR1 cells compared to the pBabe control
cell level (Fig. 5C). In LMP1-CTAR1 cells, the binding of
serine-phosphorylated STAT3 to Bcl-3-Pro, H3, and H4 was
increased 4.2-, 3-, and 4.6-fold, respectively. These data indi-
cate that LMP1-CTAR1 likely regulates Bcl-3 by increasing
the interaction of serine-phosphorylated STAT3 to multiple
binding sites that regulate Bcl-3 expression.
DISCUSSION
The induction of EGFR expression by LMP1 is likely a
contributing factor in the development of cancer. The EGFR is
frequently expressed at high levels in a variety of human can-
cers, including NPC (40, 54, 69). Stimulation of the tyrosine
kinase activity of EGFR affects multiple signaling pathways,
leading to the deregulation of cellular growth control and
tumorigenesis (5, 65). Thus, the effect of LMP1 on EGFR
expression is likely an important factor in carcinogenesis. The
unique activation of EGFR expression by LMP1-CTAR1 pro-
vides a novel system to assess the contribution of NF-B acti-
vation.
It was initially thought that p50/p50 or p52/p52 homodimers
were transcriptionally inactive, as these forms of NF-B lack
transactivation domains. However, subsequent studies deter-
mined that Bcl-3, which contains a transcriptional transactiva-
tion domain, can convert these complexes into active forms
(19, 46, 47). It is thought that one of the major functions of
Bcl-3 is to bring p50 into the nucleus, and the increased nuclear
FIG. 4. LMP1 effects on IL-6. The expression level of IL-6 mRNA
in stable C33A cells was analyzed by QRT-PCR. Severalfold change
was normalized to the value for actin. Data shown are the mean values
of four independent experiments, each being performed in triplicate.
FIG. 5. LMP1-CTAR1 induces binding of STAT3 to Bcl-3 pro-
moter and intronic enhancers. (A) Schematic representation of puta-
tive STAT binding sites. HS3 and HS4 were described in reference 4.
Bcl-3-Pro was predicted using the ALGGEN-PROMO online pro-
gram. (B) ChIP analysis using normal immunoglobulin G (IgG) (lane
2), STAT3 (lane 3), and serine-phosphorylated STAT3 (lane 4) anti-
bodies (Ab) in pBabe control- and CTAR1-expressing C33A cells.
Precipitated complexes were subjected to PCR with primer pairs spe-
cific to Bcl-3-Pro, HS3, and HS4 regions. PCR was also performed with
chromatin input (lane 1). (C) QRT-PCR was performed to amplify
ChIP products from pBabe control- and CTAR1-expressing cells. Sev-
eralfold enrichment was calculated by normalizing results from
CTAR1 cells to those from pBabe cells. Data shown are the mean
values of two independent experiments, each being performed in trip-
licate.
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presence of p50 correlates with elevated Bcl-3 in LMP1-
CTAR1-expressing cells (61, 68). It has also been suggested
that Bcl-3 might contribute to p50 activation by inhibiting the
ubiquitination and subsequent degradation of DNA-bound
p50 homodimers (7). The data presented here indicate that
Bcl-3 is also regulated by LMP1-CTAR1, resulting in increased
Bcl-3 mRNA and protein and nuclear translocation of Bcl-3.
The data also indicate that the effects of LMP1 on Bcl-3 are
linked to its effects on STAT3. STAT3 is known to be activated
in EBV-infected and LMP1-expressing epithelial cells and B-
cell lymphomas (6, 9, 10, 32, 55). The induction of IL-6 by
LMP1 can result in the activation of STAT3, and increased
IL-6 production has been detected for EBV-infected and
LMP1-expressing epithelial cells (9, 10). In multiple myeloma
cells, Bcl-3 transcription has been shown to be induced by IL-6
via STAT3 binding to intronic enhancers (4). However, as
shown here, IL-6 transcription was slightly induced in LMP1-
and CTAR1-expressing C33A cells but was induced the highest
in CTAR2-expressing cells, where no EGFR or Bcl-3 induction
was detected. In addition, treatment with recombinant IL-6 did
not increase the serine phosphorylation of STAT3 or EGFR
expression in pBabe control- or CTAR1-expressing cells (data
not shown). These data indicate that LMP1-CTAR1 mediates
the constitutive activation of STAT3 independently of effects
on IL-6. IL-6-independent STAT3 activation by EBV has been
suggested in studies where retinoic acid treatment of EBV-
immortalized B lymphocytes inhibited IL-6-dependent but not
constitutive STAT3 activation (67).
It is not yet clear what exact signaling pathways activate
STAT3 in LMP1-expressing cells. It was previously suggested
that a novel activating region between CTAR1 and CTAR2 of
LMP1 interacts with JAK3 and activates the JAK/STAT sig-
naling pathway (22). However, in EBV-transformed lympho-
blastoid cell lines, the putative activating region did not medi-
ate JAK3 association or JAK/STAT3 activation (23). In
addition, in data presented here LMP1-CTAR1 is a deletion
mutant, containing amino acids 1 to 231, that lacks this domain
yet activates STAT3 considerably more effectively than full-
length LMP1 (Fig. 3). These data indicate that the putative
JAK-binding domain is not important for LMP1-mediated
STAT3 activation in C33A cells. However, the inhibition of
this activation by cucurbitacin, which is thought to inactivate
STAT3 through inhibiting JAK2 and JAK3 activity, may indi-
cate that the regulation of JAK activity contributes to LMP1-
mediated STAT3 activation (2, 56). It will be of interest to
determine how the CTAR1/TRAF complexes possibly affect
STAT3 activity or the JAKs.
Several signaling pathways affected by LMP1 have been asso-
ciated with STAT3 activation. Serine phosphorylation of STAT3
has been shown to be mediated by phosphoinositide 3-kinase/
AKT and extracellular signal-regulated kinase (ERK) signaling
pathways, which are both activated by LMP1-CTAR1 (11, 20, 34,
35, 50, 62). Interestingly, EGFR also activates STAT3, which
suggests that a positive signaling loop of STAT33Bcl-33
EGFR3STAT3 may be established in LMP1-expressing cells
and during EBV-mediated transformation (8, 49).
A recent study suggested that LMP1 induces Bcl-3 expres-
sion through CTAR2 and the NF-B pathway (45). This study
showed that the deletion of CTAR2 or the NF-B binding sites
in the Bcl-3 promoter abolished the activity of a Bcl-3 reporter
construct in LMP1-expressing Jurkat cells. The difference be-
tween that recent study and the data presented here may re-
flect that the construct used in that study contained amino
acids 1 to 331 of the LMP1 protein, 100 amino acids longer
than the CTAR1 construct (1-231) tested in our study. This
region of amino acids 231 to 331 of LMP1 may have an inhib-
itory effect on CTAR1-mediated Bcl-3 induction. Possible in-
hibition by this domain is also suggested by the fact that
CTAR1 alone has a higher activity for inducing Bcl-3 and
EGFR than does full-length LMP1 (Fig. 1 and Fig. 2). Impor-
FIG. 6. A working model for LMP1-CTAR1-mediated induction of Bcl-3 and, consequently, EGFR.
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tantly, the LMP1-CTAR2 deletion mutant was tested using
only a Bcl-3 reporter construct, and CTAR1 was not tested for
its effects on Bcl-3 expression in cell lines. In addition, the
reporter construct did not include the STAT3-binding site lo-
cated approximately 1,200 bp upstream of the Bcl-3 transcrip-
tional start site, which had the strongest interaction with
STAT3 and serine-phosphorylated STAT3 in CTAR1-express-
ing C33A cells. This STAT3 binding site is likely important for
CTAR1-mediated Bcl-3 induction.
It is intriguing that CTAR1 had an effect considerably stron-
ger than that of full-length LMP1, although both were ex-
pressed at very similar levels. It is possible that the presence of
CTAR2 downregulates the ability of CTAR1 to induce Bcl-3
and EGFR. LMP1-CTAR2 mediates downstream signaling
pathways through TRAF2 or TRAF6, both of which are po-
tential E3 ubiquitin ligases (26, 63). Since it has been shown
that both EGFR and Bcl-3 can be regulated by ubiquitination,
it is possible that either CTAR2-recruited TRAF2 or TRAF6
affects the LMP1-mediated induction of EGFR and Bcl-3 (24,
29, 30, 36, 60).
In summary, the data here suggest a model of LMP1-medi-
ated induction of EGFR with constitutive activation of STAT3
by CTAR1 through the induction of tyrosine and serine phos-
phorylation of STAT3 (Fig. 6). The serine-phosphorylated
STAT3 would increase Bcl-3 expression through interaction
with multiple STAT-binding sites in both the promoter and
introns of Bcl-3. The increased levels of Bcl-3 and the elevated
levels of p50 form a transcriptional active complex to transac-
tivate EGFR. The link between STAT3 and EGFR has also
been shown by microarray data of epithelial cells overexpress-
ing STAT3 (64). It has been suggested that the unique activa-
tion of distinct genes by LMP1-CTAR1 reflects its activation of
the noncanonical pathway (33). However, the data presented
here reveal that LMP1-CTAR1 has an additional mechanism
to activate NF-B through its effects on STAT3 and Bcl-3. As
multiple genes have been shown to be regulated by the Bcl-3/
p50-homodimer complex, it is likely that this pathway is re-
sponsible for other genes induced by LMP1 in EBV-associated
tumorigenesis.
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